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Arthritis Post-Immunotherapy for Endometrial Cancer: A Case Report and Review 1 
of Literature on the Acute Onset of Inflammatory Arthritis Following PD-I Inhibitor 2 
Therapy in a Patient with Recurrent Endometrial Cancer  3 
 4 
Abstract  5 
 6 
Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has 7 
been utilized in the management of cancers that progress following first-line therapy.1,2,5 While 8 
the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) 9 
can be elicited and require prompt diagnosis and management based on grading and severity, 10 
which can include discontinuation of immunotherapy.6,7,10,12 Our case concerns a 66-year-old 11 
female with recurrent endometrial cancer who was treated with pembrolizumab and developed 12 
inflammatory arthritis following therapy. We provide a succinct review of the pathogenesis and 13 
risk factors associated with irAEs, as well as diagnosis and management strategies.  14 
 15 
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Introduction  21 
 22 
In the United States, endometrial cancer is the fourth most common cancer among women, and 23 
there have been recent increases in its incidence and mortality rates.1,2 Specifically, increases are 24 
noted from 49,650 cases and 8,190 deaths in 2013 to 65,620 cases and 12,590 deaths in 2020, 25 
respectively.1,3 Endometrial cancer caught in early stages can be curatively treated with surgery, 26 
radiotherapy, or chemotherapy; however, 15% of women will have recurrence following first-27 
line therapy.1,2,4 Patients diagnosed with advanced stages or disease that progresses following 28 
first-line therapy have poor prognoses. With no standard therapy protocol, the 5-year survival 29 
rate for patients with lymph node metastasis is less than 50% and for patients with peritoneal or 30 
distant metastasis is less than 20%.2 31 
  32 
Approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of 33 
advanced melanoma, pembrolizumab is an immune checkpoint inhibitor that interferes with the 34 
interaction between the programmed cell death protein 1 (PD-1) receptor expressed on the cells 35 
of the immune system and PD-1 ligand (PD-L1) expressed on tumor cells to prevent evasion of 36 
the immune system by tumor cells.5,6 Studies have demonstrated favorable results among 37 
patients who have progressed following first-line treatment, or those who have no other 38 
treatment options.1,2 However, immune related adverse events (irAEs), such as rash, colitis, and 39 
pneumonitis, are associated with this modality due to impaired self-tolerance.5,6  40 
 41 
In this case, we report a 66-year-old woman with a history of recurrent endometrial cancer 42 
treated with pembrolizumab. She subsequently presented to her gynecologic-oncologist with 43 
complaints of bilateral hand joint pain and swelling and bilateral knee pain. She was referred to 44 
rheumatology and diagnosed with inflammatory arthritis related to immunotherapy. Due to the 45 
rarity of this irAE, this case provides the opportunity to discuss the pathogenesis of irAEs 46 
1
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following treatment with immune checkpoint inhibitors, risk factors associated with irAEs, and 47 
the diagnosis and management of irAEs.  48 
 49 
Case Presentation  50 
 51 
The patient is a 66-year-old woman with no significant medical history who presented to her 52 
gynecologist with postmenopausal bleeding. She was referred to a gynecologic-oncologist after 53 
an endometrial biopsy revealed complex atypical endometrial hyperplasia. Following a total 54 
laparoscopic hysterectomy and bilateral salpingo-oophorectomy, she was diagnosed with stage 55 
IIIC endometrial cancer and started on adjuvant chemoradiation. Regimens included carboplatin 56 
and paclitaxel, as well as doxorubicin and carboplatin. Six years after the initial diagnosis, the 57 
patient was found to have recurrence of endometrial cancer and started on pembrolizumab.  58 
 59 
While the immunotherapy elicited favorable oncological response, the patient began 60 
experiencing bilateral hand joint pain and swelling, as well as bilateral knee pain seven months 61 
after the first infusion. The patient was referred to rheumatology for further evaluation. Per 62 
rheumatology records, the patient complained of pain, swelling, and stiffness of bilateral hand 63 
joints, which was worse in the morning, and general fatigue. She denied any history of joint pain 64 
or similar symptoms prior to immunotherapy infusion. On physical exam, bilateral wrists, 65 
metacarpophalangeal joints, proximal interphalangeal joints, and distal interphalangeal joints 66 
showed severe swelling, limitation of movement, and flexion deformity with incomplete fist and 67 
grip. Suspecting severe inflammatory arthritis status-post immunotherapy infusion, the patient 68 
was started on daily low-dose oral prednisone (10 mg) for symptomatic improvement. Additional 69 
work-up to differentiate inflammatory and non-inflammatory arthritis included x-ray of bilateral 70 
hands and a complete connective tissue screening profile, including rheumatoid factor (RF), 71 
anticyclic citrullinated peptide antibodies (anti-CCP), antinuclear antibodies (ANA), and C-72 
reactive protein (CRP). The patient was advised to continue all other medications, including 73 
pembrolizumab infusions, as prescribed.  74 
 75 
At two-week follow-up, the patient reported symptomatic improvement with the use of daily 76 
low-dose oral prednisone. On physical exam, bilateral wrists, metacarpophalangeal joints, 77 
proximal interphalangeal joints, and distal interphalangeal joints showed minimal swelling with 78 
improved range of motion and flexion deformity with improved fist and grip. Serology test was 79 
negative for RF, anti-CCP, and ANA; however, CRP was elevated. All other laboratory findings 80 
were within normal limits. Additionally, x-rays of bilateral hands revealed no erosions, but 81 
osteopenia was identified in both hands. While unable to definitively differentiate between 82 
inflammatory arthritis status-post immunotherapy infusions and seronegative rheumatoid 83 
arthritis, the patient responded to low-dose oral steroids, an indicator of appropriate response in 84 
the setting of immunotherapy usage. After a joint discussion between the rheumatologist and 85 
gynecologic-oncologist, the decision was made to taper the prednisone, in order to spare 86 
prolonged steroid use, and begin weekly methotrexate infusions. Four months following the 87 
initiation of methotrexate, the patient continued to receive pembrolizumab with limited reports of 88 
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Compared to traditional chemotherapies, pembrolizumab demonstrates superior efficacy and a 92 
better toxicity profile; however, due to inhibitory properties, it is still associated with adverse 93 
events.7,8 The PD-1 is a transmembrane protein that is expressed on immune cells, including 94 
cytotoxic T-cells, natural killer cells, and B-cells.4,5 Physiologically, this receptor interacts with 95 
PD-L1 during presentation of self-antigens to prevent harm to normal-functioning tissue.4,5 96 
Tumor cells harness this property in order to evade the immune system.  97 
 98 
Interestingly, tumor infiltration lymphocytes (TILs) upregulate the PD-1 receptor to increase 99 
interactions with PD-L1 in order to suppress the cytotoxic effects of T-cells and other immune 100 
cells.4,5 Pembrolizumab, an anti-PD-1 inhibitor, works against tumor cells by attaching to PD-1 101 
and blocking the site where this interaction occurs, leading to destruction of the tumor cells by 102 
immune cells.4,6 While this results in a favorable pathologic response, the system-wide inhibition 103 
can cause infiltration of normal tissue by immune cells, resulting in autoimmunity.   104 
 105 
Identifying risk factors associated with the development of irAEs in patients who receive 106 
immune checkpoint inhibitors helps to predict incidence of events and to make rapid diagnoses 107 
to begin management strategies.8 Some studies have theorized that risk factors include low 108 
muscle attenuation, chronic infections, use of medications with autoimmune side effects, and 109 
various biomarkers, such as eosinophil count.8 Kartolo et al. aimed to identify the predictors of 110 
irAEs in patients with advanced solid cancers who were treated with immune checkpoint 111 
inhibitors. Results from the study indicate protective predictors, such as corticosteroid use prior 112 
to initiation of immunotherapy and female sex, as well as harmful predictors, such as pre-113 
existing autoimmune disease, use of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 114 
inhibitors, and poor renal function.8   115 
 116 
Due to apprehension towards exacerbation of underlying autoimmune disease, there is limited 117 
research available concerning the use of immune checkpoint inhibitors in patients with pre-118 
existing autoimmune disease, and this population is often excluded from studies.4 Ramos et al. 119 
demonstrated successful oncological response following immunotherapy in a patient with 120 
recurrent endometrial cancer without aggravating her underlying p-ANCA vasculitis.4 Other 121 
studies have demonstrated similar results in patients who have systemic lupus erythematosus, 122 
rheumatoid arthritis, inflammatory bowel disease, and scleroderma.9 Therefore, patients with 123 
underlying autoimmune disease are at a higher risk for exacerbation; however, immune 124 
checkpoint inhibitors can be used in the treatment of their malignancy. 125 
 126 
Prior to initiation of immunotherapy, clinicians must provide patients and caregivers with 127 
sufficient education to identify symptoms of irAEs and screen thoroughly at each appointment 128 
thereafter.6 In efforts to standardize screening, Lidar et al. developed a screening questionnaire to 129 
assist in identifying the onset of irAEs, including questions such as, “have you suffered from 130 
arthritis?” or “do you suffer from dryness of eyes or mouth?”10 If the patient or caregiver 131 
endorses any symptoms, it is imperative to begin therapy, such as steroids, and refer to the 132 
appropriate specialty team.6,10 133 
 134 
The KEYNOTE-028 study demonstrated that 54.2% of women with advanced endometrial 135 
cancer developed irAEs following pembrolizumab therapy.2 The American Society of Clinical 136 
Oncology provides a succinct summary of management of irAEs, including the diagnostic 137 
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workup, grading, and management associated with inflammatory arthritis.11 Per 138 
recommendations, workup should include complete rheumatologic history and examination of all 139 
peripheral joints and spine, plain x-rays to evaluate for joint damage, and autoimmune panel.11 140 
IrAEs are classified based on the system effected, and severity is graded according to the 141 
Common Terminology Criteria for Adverse Events (CTCAE).6,7,8 The most common irAEs 142 
include rash, pruritus, hypophysitis, colitis, hepatitis, and pneumonitis.6,10 While most irAEs are 143 
self-limiting and mild, less than 10% are considered severe and qualify as grade three or four.8 144 
Ott et al. reported 16.7% of women enrolled in the KEYNOTE-028 study developed grade three 145 
irAEs, and none developed grade four.2 While the median onset for moderate to severe irAEs is 146 
approximately nine weeks, the median onset of rheumatological irAEs is approximately 11 147 
months.6,10  148 
 149 
Once the irAE has been diagnosed, management must begin promptly and is determined based 150 
on severity.6,10 All patients, regardless of severity, should be referred to applicable specialty 151 
teams.11 For rheumatological irAEs of mild to moderate severity, NSAIDs can be used for 152 
analgesia, and oral steroids can be used for immunomodulation.6,10,12 If management of the irAE 153 
requires a higher dose of oral steroid, or the steroid is unable to be tapered appropriately, 154 
methotrexate can be added.10 While tumor necrosis factor inhibitors are second-line therapy, they 155 
should be used with caution due to side effects and toxicity profile.10,12 Lastly, pembrolizumab 156 
therapy should be stopped if the irAE is life-threatening or severe.13  157 
 158 
Conclusion  159 
 160 
In this report, we present the case of a patient with recurrent endometrial cancer treated with 161 
pembrolizumab and the subsequent development of inflammatory arthritis, a rarely reported 162 
irAE. We have provided a literature review in order to emphasize the pathological response 163 
responsible for development of autoimmunity, risk factors associated with the use of 164 
immunotherapy, and the need for prompt diagnosis and management. It is imperative that all 165 
healthcare workers involved in the medical care of patients receiving immunotherapy understand 166 
how irAEs present in order to diagnose and manage appropriately, including prompt initiation of 167 
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